Tower Research Capital LLC TRC Purchases 5,972 Shares of Cabot Co. (NYSE:CBT)

Tower Research Capital LLC TRC increased its position in shares of Cabot Co. (NYSE:CBT) by 225.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,617 shares of the specialty chemicals company’s stock after buying an additional 5,972 shares during the period. Tower Research Capital LLC TRC’s holdings in Cabot were worth $787,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in Cabot during the fourth quarter valued at about $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Cabot by 37.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company’s stock worth $74,000 after purchasing an additional 219 shares during the last quarter. GAMMA Investing LLC boosted its stake in Cabot by 10.7% during the 4th quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company’s stock valued at $123,000 after purchasing an additional 130 shares during the period. Manchester Capital Management LLC grew its holdings in Cabot by 1,685.1% in the 4th quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company’s stock valued at $153,000 after buying an additional 1,584 shares during the last quarter. Finally, KBC Group NV increased its position in Cabot by 43.1% in the 4th quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company’s stock worth $187,000 after buying an additional 616 shares during the period. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CBT has been the topic of several research analyst reports. Mizuho lowered their price objective on shares of Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. UBS Group decreased their price target on shares of Cabot from $93.00 to $83.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. JPMorgan Chase & Co. reduced their target price on shares of Cabot from $105.00 to $85.00 and set an “underweight” rating for the company in a research note on Friday, February 21st. Finally, StockNews.com upgraded Cabot from a “hold” rating to a “buy” rating in a research note on Thursday, April 17th.

Cabot Trading Down 0.3 %

Shares of CBT stock opened at $79.27 on Friday. The firm has a fifty day moving average of $81.93 and a 200-day moving average of $93.69. The stock has a market cap of $4.30 billion, a price-to-earnings ratio of 10.53, a P/E/G ratio of 0.74 and a beta of 1.04. Cabot Co. has a 52-week low of $73.63 and a 52-week high of $117.46. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.29 and a current ratio of 2.00.

Cabot (NYSE:CBT) last posted its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. On average, equities research analysts forecast that Cabot Co. will post 7.57 earnings per share for the current fiscal year.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.